Parkside Financial Bank & Trust’s Cytek Biosciences CTKB Stock Holding History

Parkside Financial Bank & Trust’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-66	Closed	-$289	–	2728
2026 Q1	$289	Sell	66 -127	-66%	-$600	﹤0.01%	2620
2025 Q4	$976	Buy	193 +127	+192%	+$590	﹤0.01%	2355
2025 Q3	$230	Hold	66	–	–	﹤0.01%	2649
2025 Q2	$225	Buy	+66	New	+$220	﹤0.01%	2663
2025 Q1	–	Sell	-39	Closed	-$254	–	2741
2024 Q4	$254	Sell	39 -21	-35%	-$125	﹤0.01%	2015
2024 Q3	$333	Buy	60 +39	+186%	+$221	﹤0.01%	1906
2024 Q2	$118	Buy	21 +5	+31%	+$30	﹤0.01%	2011
2024 Q1	$108	Hold	16	–	–	﹤0.01%	2010
2023 Q4	$146	Sell	16 -751	-98%	-$4.73K	﹤0.01%	1996
2023 Q3	$4.23K	Buy	767 +382	+99%	+$3.06K	﹤0.01%	1427
2023 Q2	$3.29K	Buy	+385	New	+$3.45K	﹤0.01%	1520

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Parkside Financial Bank & Trust's CTKB Position: Q2 2026 in Review

Parkside Financial Bank & Trust sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 66 shares — an estimated $289 sold.

Parkside Financial Bank & Trust first reported a position in CTKB in Q2 2023 and held it in 11 quarters. The position peaked at $4.23K in Q3 2023. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Parkside Financial Bank & Trust reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
Parkside Financial Bank & Trust sold 66 Cytek Biosciences shares in Q2 2026, an estimated $289.
Parkside Financial Bank & Trust first reported a position in Cytek Biosciences in Q2 2023 and held it in 11 quarters.
Parkside Financial Bank & Trust's Cytek Biosciences position peaked at $4.23K in Q3 2023.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Parkside Financial Bank & Trust's 13F filing for Q2 2026, filed 4 Sep 2026.